Myeloma Novel Drug Discovery Ver 1.2

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

250 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-07-22

Study Completion Date

2035-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Myeloma is a bone marrow cancer with over 5000 patients diagnosed in the UK each year. Researchers are committed to improving understanding of myeloma and developing more effective treatments with fewer side effects in order to improve patient outcomes. In order to do this, researchers are collecting samples of blood and bone marrow to test the activity of potential new treatments in the laboratory and to understand what may be the cause of some treatments not working.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function

NCT00721734

Multiple Myeloma Renal Insufficiency

COMPLETED PHASE2

Lenalidomide and Melphalan in Treating Patients With Previously Untreated Multiple Myeloma

NCT00305812

Multiple Myeloma and Plasma Cell Neoplasm

COMPLETED PHASE2

Study of the Safety and Efficacy of an Investigational Drug in Adult Patients With Multiple Myeloma

NCT00036140

Multiple Myeloma

COMPLETED PHASE1

Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients

NCT05014646

Smoldering Plasma Cell Myeloma

RECRUITING PHASE2

Melphalan on Disease Burden Measured by Next Generation Sequencing Before AHCT (Autologous Hematopoietic Cell Transplant) for Multiple Myeloma

NCT05013437

Multiple Myeloma

WITHDRAWN EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple Myeloma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Participants with a diagnosis, or suspected diagnosis, of myeloma or related plasma cell disorder

Participants who are undergoing peripheral blood or bone marrow aspirate sampling for diagnostic, staging or follow-up purposes, before, whilst or after receiving anti-myeloma treatment will be approached to collect additional samples for research.

Observational study - sample collection only.

Intervention Type OTHER

No intervention - blood and/or bone marrow sample collection only

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Observational study - sample collection only.

No intervention - blood and/or bone marrow sample collection only

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Participants who have a diagnosis, or suspected diagnosis, of myeloma or related plasma cell disorder
2. Participants who are undergoing a peripheral blood or bone marrow aspirate sampling for diagnostic, staging or follow-up purposes, before, whilst or after receiving anti-myeloma treatment
3. Participants aged 18 years of age or above
4. Participants willing to consent to an additional sample being taken at the time of their peripheral blood or bone marrow aspirate sampling

Exclusion Criteria

1. Participants unable to provide consent
2. Participants with known active infectious diseases (e.g. HIV, Hepatitis B/C, COVID) that pose a risk to the use of the sample in the laboratory

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No